www.epimab.com Open in urlscan Pro
47.241.173.242  Public Scan

Form analysis
0 forms found in the DOM

Text Content

EN
CN
 * Who We Are
   About EpimAb Management Team Board of Directors Company Culture
 * Our Science
   About FIT-Ig®
 * Pipeline
   Pipeline
 * Partnering
   Partnering Strategy Existing Partnerships
 * News & Events
   News Events
 * Career
   EpimAb people Job opportunity



 * Who We Are
   About EpimAb Management Team Board of Directors Company Culture
 * Our Science
   About FIT-Ig®
 * Pipeline
   Pipeline
 * Partnering
   Partnering Strategy Existing Partnerships
 * News & Events
   News Events
 * Career
   EpimAb people Job opportunity

CN | EN

News & Events
Mar 24, 2020
EpimAb Biotherapeutics Appoints David Gu, Ph.D. as New Chief Financial Officer
to Drive Corporate Development Plans

EpimAb Biotherapeutics, an emerging Shanghai-based biopharmaceutical company
specializing in bispecific antibodies, today announced the appointment of Dr.
Xinyi “David” Gu as the new Chief Financial Officer of EpimAb, adding to the
current leadership team consisting of Chengbin Wu, Ph.D. CEO; Stephan Lensky,
Ph.D. COO and CBO; and Bin Peng, M.D., Ph.D., CMO. Dr. Gu joins EpimAb from
Millennium Management where he oversaw investments in global pharmaceutical and
biotechnology companies.

“As EpimAb continues to grow, we have reached a stage in our corporate
development where the timing is right for the creation of a dedicated Chief
Financial Officer position.” said Dr. Chengbin Wu, CEO and founder of EpimAb.
“David is an experienced healthcare analyst with a strong scientific background
and long-standing expertise that ties to capital markets. His perspectives will
be instrumental in bringing our company to the next stage of growth.”

“EpimAb’s innovative model of generating bispecific antibodies presents a unique
opportunity in the field of immuno-oncology and other therapeutic areas to bring
valuable treatments to patients,” said Dr. Gu. “I am excited to join this
accomplished team of industry leaders and look forward to contributing my
experience in the U.S. financial markets and knowledge of the biopharmaceutical
landscape to help EpimAb advance its business priorities.”

Immediately prior to joining Millennium Management, Dr. Gu was a Vice President
and Global Pharmaceutical Equity Research Analyst at Jefferies LLC, where he was
responsible for covering global large-cap pharmaceutical companies across
multiple therapeutic areas, evaluating companies for initial and secondary
public offerings, and advising clients on financial strategy and business
development. Prior to Jefferies, Dr. Gu was a management consultant at McKinsey
& Company, and also held research positions at Wells Fargo Securities. Dr. Gu
holds a Ph.D. in Pharmaceutical Sciences from the University of Michigan, and
graduated summa cum laude with a Bachelor of Science degree in Biochemistry from
the University of Illinois at Urbana-Champaign.


linkedin

wechat

Facebook

Accessibility Policy | Disclaimer | Privacy
COPYRIGHT © 2020 EPIMAB BIOTHERAPEUTICS, INC 备案号：沪ICP备16036337号-2
Powered By MANRO